WALTHAM, Mass.--(BUSINESS WIRE)--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2007 results, along with guidance for 2008, on Thursday, February 28, 2008 . A conference call and webcast will begin at 10:00 a.m. ET (7:00 a.m. PST), hosted by OXiGENE’s President and Chief Executive Officer, Dr. Richard Chin; Chief Scientific Officer, Dr. David Chaplin; Chief Medical Officer, Dr. Patricia Walicke; Chief Business Officer, John Kollins and Chief Financial Officer, James Murphy.
